Cardiovascular Safety in Drug Development and Therapeutic Use
Latest Publications

TOTAL DOCUMENTS

(FIVE YEARS 0)

H-INDEX

(FIVE YEARS 0)

Published By Springer International Publishing

9783319403458, 9783319403472

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Oncology Drug Therapy: Cardiotoxicity and the Discipline of Cardio-oncology

Cardiovascular Safety in Drug Development and Therapeutic Use ◽

10.1007/978-3-319-40347-2_10 ◽

2016 ◽

pp. 201-221

Author(s):

J. Rick Turner ◽

Dilip R. Karnad ◽

Snehal Kothari

Keyword(s):

Drug Therapy ◽

Oncology Drug

Download Full-text

The Central Role of Cardiovascular Safety in Drug Development and Therapeutic Use

Cardiovascular Safety in Drug Development and Therapeutic Use ◽

10.1007/978-3-319-40347-2_1 ◽

2016 ◽

pp. 3-20

Author(s):

J. Rick Turner ◽

Dilip R. Karnad ◽

Snehal Kothari

Keyword(s):

Drug Development ◽

Therapeutic Use ◽

Cardiovascular Safety

Download Full-text

Satisfying the Regulatory Requirements for New Antidiabetic Drugs for Type 2 Diabetes Most Expeditiously

Cardiovascular Safety in Drug Development and Therapeutic Use ◽

10.1007/978-3-319-40347-2_13 ◽

2016 ◽

pp. 251-275

Author(s):

J. Rick Turner ◽

Dilip R. Karnad ◽

Snehal Kothari

Keyword(s):

Type 2 Diabetes ◽

Antidiabetic Drugs ◽

Regulatory Requirements

Download Full-text

The Proarrhythmic Cardiac Safety Regulatory Landscape Circa 2005–2015: Drug-Induced hERG Channel Block and the Thorough QT/QTc Study

Cardiovascular Safety in Drug Development and Therapeutic Use ◽

10.1007/978-3-319-40347-2_7 ◽

2016 ◽

pp. 137-163

Author(s):

J. Rick Turner ◽

Dilip R. Karnad ◽

Snehal Kothari

Keyword(s):

Herg Channel ◽

Channel Block ◽

Cardiac Safety ◽

Drug Induced ◽

Regulatory Landscape

Download Full-text

Postmarketing Cardiovascular Safety Considerations

Cardiovascular Safety in Drug Development and Therapeutic Use ◽

10.1007/978-3-319-40347-2_14 ◽

2016 ◽

pp. 279-304

Author(s):

J. Rick Turner ◽

Dilip R. Karnad ◽

Snehal Kothari

Keyword(s):

Cardiovascular Safety ◽

Safety Considerations

Download Full-text

Analyzing and Reporting Efficacy Data

Cardiovascular Safety in Drug Development and Therapeutic Use ◽

10.1007/978-3-319-40347-2_4 ◽

2016 ◽

pp. 73-98

Author(s):

J. Rick Turner ◽

Dilip R. Karnad ◽

Snehal Kothari

Keyword(s):

Efficacy Data

Download Full-text

QTc Exposure–Response Modeling as a Primary Methodology for Proarrhythmic Cardiac Safety Assessments

Cardiovascular Safety in Drug Development and Therapeutic Use ◽

10.1007/978-3-319-40347-2_8 ◽

2016 ◽

pp. 165-180

Author(s):

J. Rick Turner ◽

Dilip R. Karnad ◽

Snehal Kothari

Keyword(s):

Cardiac Safety ◽

Exposure Response ◽

Safety Assessments ◽

Response Modeling

Download Full-text

Analyzing and Reporting Safety Data

Cardiovascular Safety in Drug Development and Therapeutic Use ◽

10.1007/978-3-319-40347-2_5 ◽

2016 ◽

pp. 99-113

Author(s):

J. Rick Turner ◽

Dilip R. Karnad ◽

Snehal Kothari

Keyword(s):

Safety Data

Download Full-text

Drug Structures and the Biological Basis of Drug Responses

Cardiovascular Safety in Drug Development and Therapeutic Use ◽

10.1007/978-3-319-40347-2_2 ◽

2016 ◽

pp. 23-49

Author(s):

J. Rick Turner ◽

Dilip R. Karnad ◽

Snehal Kothari

Keyword(s):

Drug Responses ◽

Biological Basis

Download Full-text

A Safety Perspective on Additional Aspects of Drug Development and Therapeutic Use

Cardiovascular Safety in Drug Development and Therapeutic Use ◽

10.1007/978-3-319-40347-2_15 ◽

2016 ◽

pp. 305-330

Author(s):

J. Rick Turner ◽

Dilip R. Karnad ◽

Snehal Kothari

Keyword(s):

Drug Development ◽

Therapeutic Use

Download Full-text

Cardiovascular Safety in Drug Development and Therapeutic UseLatest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Springer International Publishing

Oncology Drug Therapy: Cardiotoxicity and the Discipline of Cardio-oncology

The Central Role of Cardiovascular Safety in Drug Development and Therapeutic Use

Satisfying the Regulatory Requirements for New Antidiabetic Drugs for Type 2 Diabetes Most Expeditiously

The Proarrhythmic Cardiac Safety Regulatory Landscape Circa 2005–2015: Drug-Induced hERG Channel Block and the Thorough QT/QTc Study

Postmarketing Cardiovascular Safety Considerations

Analyzing and Reporting Efficacy Data

QTc Exposure–Response Modeling as a Primary Methodology for Proarrhythmic Cardiac Safety Assessments

Analyzing and Reporting Safety Data

Drug Structures and the Biological Basis of Drug Responses

A Safety Perspective on Additional Aspects of Drug Development and Therapeutic Use

Cardiovascular Safety in Drug Development and Therapeutic Use
Latest Publications